You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美知名組織BIO稱正採取措施剔除藥明康德會員資格 支持《生物安全法》
格隆匯 03-14 10:42
據財聯社,今日在美國知名生物技術組織BIO(Biotechnology Innovation organization)官網獲悉,BIO於美國時間3月13日發佈一則新聞稿,稱BIO目前正在採取措施,在組織成員資格方面與藥明康德(WuXi-AppTec)分開,並表示將支持《生物安全法案》,並將隨着該立法的進展與國會合作。在新聞稿中,BIO還透露其13日還致信衆議院議員、美中戰略競爭特別委員會主席邁克爾·加拉格爾(Michael Gallagher),表明其立場並強調生物技術行業對國家安全的重要性。小財注:藥明康德曾是BIO長期會員,今日在醫藥股大漲情況下,藥明系港股跌幅均在9%左右。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account